<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898920</url>
  </required_header>
  <id_info>
    <org_study_id>34585/3/21</org_study_id>
    <nct_id>NCT04898920</nct_id>
  </id_info>
  <brief_title>Pre-emptive Dexamethasone in Hip Arthroplasty</brief_title>
  <official_title>The Effect of Pre-emptive Dexamethasone on the Postoperative Analgesia After Total Hip Arthroplasty: Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Certain studies suggested that preoperative administration of systemic glucocorticoids&#xD;
           in patients undergoing hip or knee arthroplasty surgery may improve the postoperative&#xD;
           analgesia owing to their anti-inflammatory effect.&#xD;
&#xD;
        -  This study will be carried out on 70 adult patients aged 21 to 75 years admitted to&#xD;
           orthopedic operating rooms in Tanta university hospitals for hip surgery under spinal&#xD;
           anesthesia. Informed written consent will be obtained from each participant.&#xD;
&#xD;
        -  Patients will be randomly distributed into two equal groups using the computer-generated&#xD;
           software.&#xD;
&#xD;
             -  Control Group: (35 patients) Those patients will receive 10 ml of normal saline&#xD;
                before surgery.&#xD;
&#xD;
             -  Dexamethasone Group: (35 patients) Those patients will receive 16 mg dexamethasone&#xD;
                in 10 ml of normal saline before surgery.&#xD;
&#xD;
        -  Primary outcome will be postoperative morphine consumption and the secondary outcome&#xD;
           will be the postoperative pain score&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - This randomized controlled prospective study will be carried out on 70 adult patients aged&#xD;
      21 to 75 years admitted to orthopedic operating rooms in Tanta University Hospital for hip&#xD;
      surgery under spinal anesthesia. I&#xD;
&#xD;
      Patients will be randomly distributed into two equal groups using the computer-generated&#xD;
      software. An anesthesia resident who will be blinded to the study groups and not&#xD;
      participating in it will help in the preparation of uniform 10-ml syringes that contain&#xD;
      normal saline in the control group and 16 mg dexamethasone in the other group.&#xD;
&#xD;
        -  Control Group: (35 patients) Those patients will receive 10 ml of normal saline before&#xD;
           surgery.&#xD;
&#xD;
        -  Dexamethasone Group: (35 patients) Those patients will receive 16 mg dexamethasone in 10&#xD;
           ml of normal saline before surgery.&#xD;
&#xD;
      All the patients will undergo standardized preoperative assessment consisted of history&#xD;
      taking, general and regional examination, and requesting preoperative investigations&#xD;
      including (complete blood count (CBC), coagulation profile, and renal function tests). Upon&#xD;
      patient admission to the operating theater, they will be attached to a monitor consisting of&#xD;
      pulse oximetry, 5 lead ECG, non-invasive blood pressure, end-tidal carbon dioxide (Co2), and&#xD;
      temperature. Then, intravenous access will be established through the insertion of an&#xD;
      18-gauge peripheral venous cannula, then, lactated ringer solution 7ml/kg over 30 minutes&#xD;
      will be started. All the equipment required for spinal anesthesia, general anesthesia, and&#xD;
      nerve block will be prepared by an expert anesthesiologist who will not be participating in&#xD;
      this research. Also, the resuscitation equipment will be prepared before starting anesthesia.&#xD;
&#xD;
      Under complete aseptic precautions and local anesthetic skin infiltration with 3 ml lidocaine&#xD;
      1% at L3-L4 or L4-L5 intervertebral space, midline approach spinal anesthesia will be&#xD;
      performed using a 25 G spinal needle. Once intrathecal placement will be confirmed, a mixture&#xD;
      of 2 ml of hyperbaric bupivacaine (10 mg) and 0.5 ml of fentanyl (25 ugs) will be injected.&#xD;
      The patient will be monitored for the hemodynamic parameters including the heart rate and the&#xD;
      mean arterial pressure every 3 minutes. Moreover, the sensory and motor blockade will be&#xD;
      assessed.&#xD;
&#xD;
      Oxygen will be applied to the patient with the aid of an oxygen mask at a flow rate of 4&#xD;
      L/min. The pinprick test from caudal to cephalic direction using a 26-gauge needle will be&#xD;
      used to evaluate the sensory block until the sensory level reached the level of T11 or&#xD;
      higher. The motor block will be assessed every 5 minutes by the Bromage score (grade 3: no&#xD;
      movement, grade 2: unable to flex knees and can flex ankle, grade 1: unable to raise an&#xD;
      extended leg but able to move the knees and ankles, grade 0: no paralysis) until reaching a&#xD;
      score of 2 or 3. If no adequate sensory or motor blockade will be obtained within 20 minutes,&#xD;
      the patient will receive general anesthesia and be excluded from the study. A decrease in the&#xD;
      heart rate below 50 b/min will be managed by atropine 0.3 mg i.v, while a decrease in the&#xD;
      mean arterial pressure below 65 mmHg will be managed by 10 mg ephedrine i.v and intravenous&#xD;
      fluids.&#xD;
&#xD;
      Primary outcome will be postoperative morphine consumption and the secondary outcome will be&#xD;
      the postoperative pain score&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2021</start_date>
  <completion_date type="Anticipated">November 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>An anesthesia resident who will be blinded to the study groups and not participating in it will help in the preparation of uniform 10-ml syringes that contain normal saline in the control group and 16 mg dexamethasone in the other group to make the patient and care provider blinded to the group of the patient.&#xD;
An assistant nurse who will be blinded to the study groups and will have no subsequent rule in it will help in the collection of the data of measurements to make the outcomes assessor blinded to the group of the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>The first postoperative day</time_frame>
    <description>The total dose of morphine in mg consumed in the first 24 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>The first postoperative day</time_frame>
    <description>Postoperative Numerical Rating score (NRS) will be assessed every 2 hours in the first six hours, then every 6 hours till 24 hour.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>The patients will receive 10 ml of normal saline as a placebo dexamethasone before surgery.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Those patients will receive 16 mg dexamethasone in 10 ml of normal saline before surgery.</description>
    <arm_group_label>Dexamethasone Group</arm_group_label>
    <other_name>Active group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ASA II and III, aged 21 to 75 years, admitted for hip arthroplasty surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refused to participate in the research&#xD;
&#xD;
          -  Suspected or diagnosed coagulopathy&#xD;
&#xD;
          -  Allergy to bupivacaine&#xD;
&#xD;
          -  With major cardiac, renal, or hepatic disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameh Abdelkhalik, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sameh Abdelkhalik, M.D</last_name>
    <phone>01002977048</phone>
    <phone_ext>002</phone_ext>
    <email>samehabdelkhalik1982@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soher Soliman, Prof</last_name>
    <phone>01283929049</phone>
    <phone_ext>002</phone_ext>
    <email>sohairsoliman@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Tanta</city>
        <state>Algharbia</state>
        <zip>31511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sameh Ismaiel, M.D</last_name>
      <phone>00201002977048</phone>
      <email>samehabdelkhalik1982@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Abduallah, M.D</last_name>
      <phone>00201099957971</phone>
      <email>moh_aly_2005@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sameh Abdelkhalik Ahmed Ismaiel</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Hip arthroplasty</keyword>
  <keyword>Postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data of primary outcome will be available with the corresponding author till 6 months after approval of the publication of the trial.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The data of primary outcome will be available with the corresponding author till 6 months after approval of the publication of the trial.</ipd_time_frame>
    <ipd_access_criteria>Contact the principal investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

